Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZEA9X)

Drug Name
BIW-8962 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMZEA9X

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ganglioside GM2 activator (GM2A) TTGOFW6 SAP3_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Ganglioside GM2 activator (GM2A) DTT GM2A 4.722 5.391 4.555 4.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ganglioside GM2 activator (GM2A) DTT GM2A 1.75E-01 0.2 0.4
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01898156) Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer. U.S. National Institutes of Health.
2 Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63.